299 related articles for article (PubMed ID: 37387450)
1. CYLD in health and disease.
Marín-Rubio JL; Raote I; Inns J; Dobson-Stone C; Rajan N
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37387450
[TBL] [Abstract][Full Text] [Related]
2. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus-Associated Head and Neck Cancers.
Cui Z; Kang H; Grandis JR; Johnson DE
Mol Cancer Res; 2021 Jan; 19(1):14-24. PubMed ID: 32883697
[TBL] [Abstract][Full Text] [Related]
3. The E3 ubiquitin ligase MIB2 enhances inflammation by degrading the deubiquitinating enzyme CYLD.
Uematsu A; Kido K; Takahashi H; Takahashi C; Yanagihara Y; Saeki N; Yoshida S; Maekawa M; Honda M; Kai T; Shimizu K; Higashiyama S; Imai Y; Tokunaga F; Sawasaki T
J Biol Chem; 2019 Sep; 294(38):14135-14148. PubMed ID: 31366726
[TBL] [Abstract][Full Text] [Related]
4. Update of cylindromatosis gene (CYLD) mutations in Brooke-Spiegler syndrome: novel insights into the role of deubiquitination in cell signaling.
Blake PW; Toro JR
Hum Mutat; 2009 Jul; 30(7):1025-36. PubMed ID: 19462465
[TBL] [Abstract][Full Text] [Related]
5. Catalytic domain mutation in CYLD inactivates its enzyme function by structural perturbation and induces cell migration and proliferation.
Johari T; Maiti TK
Biochim Biophys Acta Gen Subj; 2018 Sep; 1862(9):2081-2089. PubMed ID: 29807073
[TBL] [Abstract][Full Text] [Related]
6. Immune dysregulation in SHARPIN-deficient mice is dependent on CYLD-mediated cell death.
Ang RL; Chan M; Legarda D; Sundberg JP; Sun SC; Gillespie VL; Chun N; Heeger PS; Xiong H; Lira SA; Ting AT
Proc Natl Acad Sci U S A; 2021 Dec; 118(50):. PubMed ID: 34887354
[TBL] [Abstract][Full Text] [Related]
7. CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma.
Williams EA; Montesion M; Sharaf R; Corines J; Patel PJ; Gillespie BJ; Pavlick DC; Sokol ES; Alexander BM; Williams KJ; Elvin JA; Ross JS; Ramkissoon SH; Hemmerich AC; Tse JY; Mochel MC
Mod Pathol; 2020 Dec; 33(12):2614-2625. PubMed ID: 32461623
[TBL] [Abstract][Full Text] [Related]
8. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes.
Sun SC
Cell Death Differ; 2010 Jan; 17(1):25-34. PubMed ID: 19373246
[TBL] [Abstract][Full Text] [Related]
9. Loss of the tumor suppressor CYLD enhances Wnt/beta-catenin signaling through K63-linked ubiquitination of Dvl.
Tauriello DV; Haegebarth A; Kuper I; Edelmann MJ; Henraat M; Canninga-van Dijk MR; Kessler BM; Clevers H; Maurice MM
Mol Cell; 2010 Mar; 37(5):607-19. PubMed ID: 20227366
[TBL] [Abstract][Full Text] [Related]
10. CYLD dysregulation in pathogenesis of sporadic inclusion body myositis.
Yamashita S; Matsuo Y; Tawara N; Hara K; Yamamoto M; Nishikami T; Kawakami K; Zhang X; Zhang Z; Doki T; Ando Y
Sci Rep; 2019 Aug; 9(1):11606. PubMed ID: 31406156
[TBL] [Abstract][Full Text] [Related]
11. Premature aging and cancer development in transgenic mice lacking functional CYLD.
Alameda JP; Ramírez Á; García-Fernández RA; Navarro M; Page A; Segovia JC; Sanchez R; Suárez-Cabrera C; Paramio JM; Bravo A; Fernández-Aceñero MJ; Casanova ML
Aging (Albany NY); 2019 Jan; 11(1):127-159. PubMed ID: 30631004
[TBL] [Abstract][Full Text] [Related]
12. The deubiquitinase CYLD controls protective immunity against helminth infection by regulation of Treg cell plasticity.
Lee JH; Zou L; Yang R; Han J; Wan Q; Zhang X; El Baghdady S; Roman A; Elly C; Jin HS; Park Y; Croft M; Liu YC
J Allergy Clin Immunol; 2021 Jul; 148(1):209-224.e9. PubMed ID: 33309741
[TBL] [Abstract][Full Text] [Related]
13. Optineurin is required for CYLD-dependent inhibition of TNFα-induced NF-κB activation.
Nagabhushana A; Bansal M; Swarup G
PLoS One; 2011 Mar; 6(3):e17477. PubMed ID: 21408173
[TBL] [Abstract][Full Text] [Related]
14. CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation.
Zhang LM; Zhou JJ; Luo CL
Arthritis Res Ther; 2018 Oct; 20(1):219. PubMed ID: 30285829
[TBL] [Abstract][Full Text] [Related]
15. Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines.
Çalışkan C; Pehlivan M; Yüce Z; Sercan O
Mol Biol Rep; 2017 Oct; 44(5):391-397. PubMed ID: 28840581
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning and functional analysis of deubiquitinase CYLD in rainbow trout, Oncorhynchus mykiss.
Jang JH; Lee HM; Kim H; Cho JH
Fish Shellfish Immunol; 2020 Jun; 101():135-142. PubMed ID: 32224281
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating activity of CYLD is impaired by SUMOylation in neuroblastoma cells.
Kobayashi T; Masoumi KC; Massoumi R
Oncogene; 2015 Apr; 34(17):2251-60. PubMed ID: 24909169
[TBL] [Abstract][Full Text] [Related]
18. Subquinocin, a small molecule inhibitor of CYLD and USP-family deubiquitinating enzymes, promotes NF-κB signaling.
Yamanaka S; Sato Y; Oikawa D; Goto E; Fukai S; Tokunaga F; Takahashi H; Sawasaki T
Biochem Biophys Res Commun; 2020 Mar; 524(1):1-7. PubMed ID: 31898971
[TBL] [Abstract][Full Text] [Related]
19. Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.
Cranston A; Stocken DD; Stamp E; Roblin D; Hamlin J; Langtry J; Plummer R; Ashworth A; Burn J; Rajan N
Trials; 2017 Mar; 18(1):111. PubMed ID: 28270164
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of deubiquitinase CYLD enhances therapeutic antibody production in Chinese hamster ovary cells.
Lu Y; Zhou Q; Han Q; Wu P; Zhang L; Zhu L; Weaver DT; Xu C; Zhang B
Appl Microbiol Biotechnol; 2018 Jul; 102(14):6081-6093. PubMed ID: 29766242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
